Form 4 for AKBA Akebia Therapeutics, Inc.
Accepted 2022-06-10 00:00:00 ET · period of report 2022-06-08 · accession 0001562180-22-005001 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-06-10 | 2022-06-08 | AKBA | Spellman David A | SVP, CFO, Treas | A - Grant | $0.00 | +200.0K | 328.6K | +156% | $0 |
| D | 2022-06-10 | 2022-06-08 | AKBA | Spellman David A | SVP, CFO, Treas | A - Grant | $0.00 | +200.0K | 200.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-06-08 | A | A | 200,000 | $0.00 | 328,599 | D | — | — | (F1) The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended (the "2014 Plan"). The RSUs will vest in full (100%) on May 12, 2023, subject to the Reporting Person's continued service with the Issuer on such vesting date. |
| 2 | Derivative | Stock Option (Right to buy) | 2022-06-08 | A | A | 200,000 | $0.00 | 200,000 | D | $0.45 · 2023-05-12 to 2032-06-08 | 200,000 Common Stock | (F2) The option to purchase shares of the Issuer's common stock ("the Stock Option") was granted by the Issuer pursuant to the 2014 Plan. The Stock Option will vest and become exercisable in full (100%) on May 12, 2023, subject to the Reporting Person's continued service with the Issuer on such vesting date. |